Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

N 0923

Known as: N-0923 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
N‐0923 is a non‐ergot, dopaminergic D2 agonist designed to be transdermally available. It has anti‐parkinsonian effects when… Expand
2001
2001
N-0923 is a non-ergot, dopaminergic D(2) agonist designed to be transdermally available. It has anti-parkinsonian effects when… Expand
1999
1999
Nicotine, the soluble methyl ester of L-DOPA, and the D(2) agonist N-0923 were given alone and in combination im to five… Expand
1998
1998
N‐0923, a novel aminotetralin dopamine D2 agonist, was shown to effectively reverse parkinsonian symptoms in nine dopa/agonist… Expand
Highly Cited
1995
Highly Cited
1995
The potencies for in vivo inhibition of substantia nigra pars compacta dopamine single cell firing were determined for… Expand
Highly Cited
1994
Highly Cited
1994
Certain aminotetralins are known to be potent dopamine D2 receptor agonists. N‐0923, [‐]2‐(N‐propyl‐N‐2‐thienylethylamino)‐5… Expand
1993
1993
Using the hippocampal-slice preparation, we attempted to model operant conditioning in vitro by reinforcing pyramidal cell… Expand
1993
1993
The pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (1, N-0923) after… Expand
1993
1993
  • E. Domino, J. Sheng
  • The Journal of pharmacology and experimental…
  • 1993
  • Corpus ID: 22869683
A series of dopamine agonists were studied on contraversive circling behavior in seven 1-methyl-4-phenyl-1,2,3,6… Expand
1992
1992
The absorption of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxy-tetralin hydrochloride (1; N-0923… Expand